Tempest Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $1.00K.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-12-31 was $41.00K, a 46.43% increase year-over-year.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $48.00K, a 269.23% increase year-over-year.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $29.00K, a 1350.00% increase year-over-year.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.00K.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $139.00K, a 104.41% increase from fiscal 2020.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $68.00K, a 81.16% decline from fiscal 2019.
- Tempest Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $361.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-12-31 | $1.00K 10-K · filed 2025-03-27 | |
| 2023-06-30 | $1.00K 10-Q · filed 2024-11-12 | |
| 2021-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $139.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $48.00K 10-Q · filed 2022-11-08 | $125.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $29.00K 10-Q · filed 2022-11-08 | $90.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-03-31 | $20.00K 10-Q · filed 2022-11-08 | $63.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2020-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $68.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $13.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.00K 10-Q · filed 2020-08-10 | |
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $361.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $194.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $166.00K 10-Q · filed 2020-08-10 | |
| 2016-12-31 | $224.00K 10-K · filed 2018-03-15 | |
| 2015-12-31 | $1.44M 10-K · filed 2018-03-15 | |
| 2014-12-31 | $163.00K 10-K · filed 2017-03-02 | |
| 2013-12-31 | $42.00K 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |